Antimicrobial molecular nanocarrier–drug conjugates

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 8, 2016, Pages 2215-2240

  Skwarecki, Andrzej S ^a   Milewski, Sławomir ^a   Schielmann, Marta ^a   Milewska, Maria J ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Carbon nanotubes; Dendrimers; Molecular umbrellas; Peptides; Siderophores; Terpenoids

Indexed keywords

BIOLOGICAL MEMBRANES; CARBON; CARBON NANOTUBES; CYTOLOGY; DENDRIMERS; ENZYME ACTIVITY; LIPIDS; MICROORGANISMS; NANOTUBES; PEPTIDES; YARN;

CELL-PENETRATING PEPTIDE; FUTURE PERSPECTIVES; MOLECULAR UMBRELLAS; MYCOBACTERIUM TUBERCULOSIS; PATHOGENIC MICROBES; PLASMODIUM FALCIPARUM; SIDEROPHORES; TERPENOIDS;

ANTIMICROBIAL AGENTS;

ANTIINFECTIVE AGENT; CARBON NANOTUBE; CELL PENETRATING PEPTIDE; DENDRIMER; NANOCARRIER; OLIGOPEPTIDE; SIDEROPHORE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; BIOLOGICAL ACTIVITY; CANDIDA ALBICANS; DRUG CONJUGATION; DRUG UPTAKE; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; NONHUMAN; PHOTOSENSITIZATION; PSEUDOMONAS AERUGINOSA; REVIEW; DRUG EFFECTS; MYCOBACTERIUM TUBERCULOSIS;

ANTI-INFECTIVE AGENTS; CELL-PENETRATING PEPTIDES; MYCOBACTERIUM TUBERCULOSIS; NANOTUBES, CARBON; OLIGOPEPTIDES;

EID: 84983781355     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.06.002     Document Type: Review

References (173)

1. 1 Spellberg, B., The future of antibiotics. Crit Care, 18, 2014, e228.
2. 2 Pelgrift, R.Y., Friedman, A.J., Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev 65 (2013), 1803–1815.
3. 3 Abed, N., Couvreur, P., Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Int J Antimicrob Agents 43 (2014), 485–496.
4. 4 Huh, A.J., Kwon, Y.J., “Nanoantibiotics”: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release 156 (2011), 128–145.
5. 5 Xie, S., Tao, Y., Pan, Y., Qu, W., Cheng, G., Huang, Chen D., et al. Biodegradable nanoparticles for intracellular delivery of antimicrobial agents. J Control Release 187 (2014), 101–117.
6. 6 Fickel, T.E., Gilvarg, C., Transport of impermeant substances in E. coli by way of oligopeptide permease. Nature 241 (1973), 161–163.
7. 6 Ames, B.N., Ames, G.F., Young, J.D., Tsuchiya, D., Lecocq, J., Illicit transport: the oligopeptide permease. Proc Natl Acad Sci U S A 70 (1973), 456–458.
8. 7 Allen, J.G., Atherton, F.R., Hall, M.J., Hassall, C.H., Holmes, S.W., Lambert, R.W., et al. Phosphonopeptides, a new class of synthetic antibacterial agents. Nature 272 (1978), 56–58.
9. 8 Atherton, F.R., Hassall, C.H., Lambert, R.W., Synthesis and structure–activity relationships of antibacterial phosphonopeptides incorporating (1-aminoethyl)phosphonic acid and (aminomethyl)phosphonic acid. J Med Chem 29 (1986), 29–40.
10. 3-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid oligopeptides. J Med Chem 33 (1990), 132–135.
11. 10 Wakieć, R., Gabriel, I., Prasad, R., Becker, J.M., Payne, J.W., Milewski, S., Enhanced susceptibility to antifungal oligopeptides in yeast strains overexpressing ABC multidrug efflux pumps. Antimicrob Agents Chemother 52 (2008), 4057–4065.
12. 11 Milewski, S., Chmara, H., Andruszkiewicz, R., Borowski, E., Zaremba, M., Borowski, J., Antifungal peptides with novel specific inhibitors of glucosamine 6-phosphate synthase. Drugs Exp Clin Res 14 (1988), 461–465.
13. 12 Basrai, M.A., Zhang, H.L., Miller, D., Naider, F., Becker, J.M., Toxicity of oxalysine and oxalysine-containing peptides against Candida albicans: regulation of peptide transport by amino acids. Microbiology 138 (1992), 2353–2362.
14. 13 Kingsbury, W.D., Boehm, J.C., Mehta, R.J., Grappel, S.F., Transport of antimicrobial agents using peptide carrier systems: anticandidal activity of m-fluorophenylalanine–peptide conjugates. J Med Chem 26 (1983), 1725–1729.
15. 14 Ti, J.S., Steinfeld, A.S., Naider, F., Gulumoglu, A., Lewis, S.V., Becker, J.M., Anticandidal activity of pyrimidine–peptide conjugates. J Med Chem 23 (1980), 913–918.
16. 15 Kingsbury, W.D., Boehm, J.C., Mehta, R.J., Grappel, S.F., Gilvarg, C., A novel peptide delivery system involving peptidase activated prodrugs as antimicrobial agents. Synthesis and biological activity of peptidyl derivatives of 5-fluorouracil. J Med Chem 27 (1984), 1447–1451.
17. 16 Hwang, S.Y., Berges, D.A., Taggart, J.J., Gilvarg, C., Portage transport of sulfanilamide and sulfanilic acid. J Med Chem 32 (1989), 694–698.
18. 17 Milewski, S., Andruszkiewicz, R., Borowski, E., Substrate specificity of peptide permeases in Candida albicans. FEMS Microbiol Lett 50 (1988), 73–78.
19. 18 Payne, J.W., Smith, M.W., Peptide transport by micro-organisms. Adv Microb Physiol 36 (1994), 1–80.
20. 19 Reissmann, S., Cell penetration: scope and limitations by the application of cell-penetrating peptides. J Pept Sci 20 (2014), 760–784.
21. 20 Vives, E., Brodin, P., Lebleu, B., A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272 (1997), 16010–16017.
22. 21 Derossi, D., Joliot, A.H., Chassaing, G., Prochiantz, A., The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269 (1994), 10444–10450.
23. 22 Wang, F., Wang, Y., Zhang, X., Zhang, W., Guo, S., Jin, F., Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J Control Release 174 (2014), 126–136.
24. 23 Ruczyński, J., Wierzbicki, P.M., Kogut-Wierzbicka, M., Mucha, P., Siedlecka-Kroplewska, K., Rekowski, P., Cell-penetrating peptides as a promising tool for delivery of various molecules into the cells. Folia Histochem Cytobiol 52 (2014), 257–269.
25. 24 Di Pisa, M., Chassaing, G., Święcicki, J.M., Translocation mechanism(s) of cell-penetrating peptides: biophysical studies using artificial membrane bilayers. Biochemistry 54 (2015), 194–207.
26. 25 Ramsey, J.D., Flynn, N.H., Cell-penetrating peptides transport therapeutics into cells. Pharmacol Ther 154 (2015), 78–86.
27. 26 Samuel, B.U., Hearn, B., Mack, D., Wender, P., Rothbard, J., Kirisits, M.J., et al. Delivery of antimicrobials into parasites. Proc Natl Acad Sci U S A 100 (2003), 14281–14286.
28. 27 Arnusch, C.J., Ulm, H., Josten, M., Shadkchan, Y., Osherov, N., Sahl, H.-G., et al. Ultrashort peptide bioconjugates are exclusively antifungal agents and synergize with cyclodextrins and amphotericin B. Antimicrob Agents Chemother 56 (2012), 1–9.
29. 28 Ferreira, S.Z., Carneiro, H.C., Lara, H.A., Alves, R.B., Resende, J.M., Oliveira, H.M., et al. Synthesis of a new peptide–coumarin conjugate: a potential agent against cryptococcosis. ACS Med Chem Lett 6 (2015), 271–275.
30. 29 Purkayastha, N., Capone, S., Beck, A.K., Seebach, D., Antibacterial activity of enrofloxacin and ciprofloxacin derivatives of β-octaarginine. Chem Biodivers 12 (2015), 179–193.
31. 30 Jain, A., Shah, S.G., Chugh, A., Cell penetrating peptides as efficient nanocarriers for delivery of antifungal compound, Natamycin for the treatment of fungal keratitis. Pharm Res 32 (2015), 1920–1930.
32. 31 Sparr, C., Purkayastha, N., Kolesińska, B., Gengenbacher, M., Amulic, B., Matuschewski, K., et al. Improved efficacy of fosmidomycin against Plasmodium and Mycobacterium species by combination with the cell-penetrating peptide octaarginine. Antimicrob Agents Chemother 57 (2013), 4689–4698.
33. 32 Shi, N.Q., Qi, X.R., Xiang, B., Zhang, Y., A survey on “Trojan Horse” peptides: opportunities, issues and controlled entry to “Troy”. J Control Release 194 (2014), 53–70.
34. 33 Wandersman, C., Delepelaire, P., Bacterial iron sources: from siderophores to hemophores. Annu Rev Microbiol 58 (2004), 611–647.
35. 34 Miethke, M., Marahiel, M.A., Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 71 (2007), 413–451.
36. 35 Hider, R.C., Konga, X., Chemistry and biology of siderophores. Nat Prod Rep 27 (2010), 637–657.
37. 36 Braun, V., Pramanik, A., Gwinner, T., Köberle, M., Bohn, E., Sideromycins: tools and antibiotics. Biometals 22 (2009), 3–13.
38. 37 Thomas, X., Destoumieux-Garzón, D., Peduzzi, J., Afonso, C., Blond, A., Birlirakis, N., et al. Siderophore peptide, a new type of post-translationally modified antibacterial peptide with potent activity. J Biol Chem 279 (2004), 28233–28242.
39. 38 Braun, V., Günthner, H., Hantke, K., Zimmerman, L., Intracellular activation of albomycin in Escherichia coli and Salmonella typhimurium. J Bacteriol 156 (1983), 308–315.
40. 39 Roosenberg, J.M., Miller, M.J., Total synthesis of the siderophore danoxamine. J Org Chem 65 (2000), 4833–4838.
41. 40 Pramanik, A., Stroeher, U.H., Krejci, J., Standish, A.J., Bohn, E., Paton, J.C., et al. Albomycin is an effective antibiotic, as exemplified with Yersinia enterocolitica and Streptococcus pneumoniae. Int J Med Microbiol 297 (2007), 459–469.
42. 41 Hartmann, A., Fiedler, H.-P., Braun, V., Uptake and conversion of the antibiotic albomycin by Escherichia coli K-12. Eur J Biochem 99 (1979), 517–524.
43. 42 Miyakawa, S., Noto, T., Okazaki, H., Mechanism of resistance in Escherichia coli to the sideromycin antibiotic no 216: isolation and characterization of the resistant mutants. Microbiol Immunol 26 (1982), 885–895.
44. 43 Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E. Jr., Gilbert, D., Rice, L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48 (2009), 1–12.
45. 44 Md-Saleh, S.R., Chilvers, E.C., Kerr, K.G., Milner, S.J., Snelling, A.M., Weber, J.P., et al. Synthesis of citrate–ciprofloxacin conjugates. Bioorg Med Chem Lett 19 (2009), 1496–1498.
46. 45 Milner, S.J., Snelling, A.M., Kerr, K.G., Abd-El-Aziz, A., Thomas, G.H., Hubbard, R.E., et al. Probing linker design in citric acid–ciprofloxacin conjugates. Bioorg Med Chem 22 (2014), 4499–4505.
47. 46 Milner, S.J., Seve, A., Snelling, A.M., Thomas, G.H., Kerr, K.G., Routledge, A., et al. Staphyloferrin A as siderophore-component in fluoroquinolone-based Trojan horse antibiotics. Org Biomol Chem 11 (2013), 3461–3468.
48. 47 Brochu, A., Brochu, N., Nicas, T.I., Parr, T.R. Jr., Minnick, A.A. Jr., Dolence, E.K., et al. Modes of action and inhibitory activities of new siderophore–β-lactam conjugates that use specific iron uptake pathways for entry into bacteria. Antimicrob Agents Chemother 36 (1992), 2166–2175.
49. 48 Ghosh, M., Miller, M.J., Iron transport-mediated drug delivery: synthesis and biological evaluation of cyanuric acid-based siderophore analogs and β-lactam conjugates. J Org Chem 59 (1994), 1020–1026.
50. 49 Ghosh, M., Miller, M.J., Design, synthesis, and biological evaluation of isocyanurate based antifungal and macrolide antibiotic conjugates: iron transport-mediated drug delivery. Bioorg Med Chem 3 (1995), 1519–1525.
51. 50 Wencewicz, T.A., Möllmann, U., Long, T.E., Miller, M.J., Is drug release necessary for antimicrobial activity of siderophore–drug conjugates? Syntheses and biological studies of the naturally occurring salmycin “Trojan Horse” antibiotics and synthetic desferridanoxamine–antibiotic conjugates. Biometals 22 (2009), 633–648.
52. 51 Wencewicz, T.A., Long, T.E., Möllmann, U., Miller, M.J., Trihydroxamate siderophore–fluoroquinolone conjugates are selective sideromycin antibiotics that target Staphylococcus aureus. Bioconjug Chem 24 (2013), 473–486.
53. 52 Juárez-Hernández, R.E., Miller, P.A., Miller, M.J., Syntheses of siderophore–drug conjugates using a convergent thiol–maleimide system. ACS Med Chem Lett 3 (2012), 799–803.
54. 53 Yoganathan, S., Sit, C.S., Vederas, J.C., Chemical synthesis and biological evaluation of gallidermin–siderophore conjugates. Org Biomol Chem 9 (2011), 2133–2141.
55. 54 Ji, C., Miller, M.J., Chemical syntheses and in vitro antibacterial activity of two desferrioxamine B-ciprofloxacin conjugates with potential esterase and phosphatase triggered drug release linkers. Bioorg Med Chem 20 (2012), 3828–3836.
56. 55 Ji, C., Miller, M.J., Siderophore–fluoroquinolone conjugates containing potential reduction-triggered linkers for drug release: synthesis and antibacterial activity. Biometals 28 (2015), 541–551.
57. 56 Bernier, G., Girijavallabhan, V., Murray, A., Niyaz, N., Ding, P., Miller, M.J., et al. Desketoneoenactin–siderophore conjugates for Candida: evidence of iron transport-dependent species selectivity. Antimicrob Agents Chemother 49 (2005), 241–248.
58. 57 Lu, Y., Miller, M.J., Synthesis and studies of multiwarhead siderophore–5-fluorouridine conjugates. Bioorg Med Chem 7 (1999), 3025–3038.
59. 58 Pollack, S., Rossan, R.N., Davidson, D.E., Escajadillo, A., Desferrioxamine suppresses Plasmodium falciparum in Aotus monkeys. Proc Soc Exp Biol Med 184 (1987), 162–164.
60. 59 Glickstein, H., Breuer, W., Loyevsky, M., Konijn, A.M., Libman, J., Shanzer, A., et al. Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells. Blood 87 (1996), 4871–4878.
61. 60 Ghosh, M., Lambert, L.J., Huber, P.W., Miller, M.J., Synthesis, bioactivity, and DNA-cleaving ability of desferrioxamine B-nalidixic acid and anthraquinone carboxylic acid conjugates. Bioorg Med Chem Lett 5 (1995), 2337–2340.
62. 61 Ohi, N., Aoki, B., Shinozaki, T., Moro, K., Kuroki, T., Noto, T., et al. Semisynthetic beta-lactam antibiotics. IV. Synthesis and antibacterial activity of new ureidocephalosporin and ureidocephamycin derivatives containing a catechol moiety or its acetate. Chem Pharm Bull (Tokyo) 35 (1987), 1903–1909.
63. 62 Heinisch, L., Wittmann, S., Stoiber, T., Berg, A., Ankel-Fuchs, D., Möllmann, U., Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds. J Med Chem 45 (2002), 3032–3040.
64. 63 Wittmann, S., Schnabelrauch, M., Scherlitz-Hofmann, I., Möllmann, U., Ankel-Fuchs, D., Heinisch, L., New synthetic siderophores and their β-lactam conjugates based on diamino acids and dipeptides. Bioorg Med Chem 10 (2002), 1659–1670.
65. 64 Möllmann, U., Heinisch, L., Bauernfeind, A., Köhler, T., Ankel-Fuchs, D., Siderophores as drug delivery agents: application of the “Trojan Horse” strategy. Biometals 22 (2009), 615–624.
66. 65 Ji, C., Miller, P.A., Miller, M.J., Iron transport-mediated drug delivery: practical syntheses and in vitro antibacterial studies of tris-catecholate siderophore–aminopenicillin conjugates reveals selectively potent antipseudomonal activity. J Am Chem Soc 134 (2012), 9898–9901.
67. 66 Zheng, T., Nolan, E.M., Enterobactin-mediated delivery of β-lactam antibiotics enhances antibacterial activity against pathogenic Escherichia coli. J Am Chem Soc 136 (2014), 9677–9691.
68. 67 Fardeau, S., Dassonville-Klimpt, A., Audic, N., Sasaki, A., Pillon, M., Baudrin, E., et al. Synthesis and antibacterial activity of catecholate–ciprofloxacin conjugates. Bioorg Med Chem 22 (2014), 4049–4060.
69. 68 Zheng, T., Nolan, E.M., Evaluation of (acyloxy)alkyl ester linkers for antibiotic release from siderophore–antibiotic conjugates. Bioorg Med Chem Lett 25 (2015), 4987–4991.
70. 69 Paulen, A., Gasser, V., Hoegy, F., Perraud, Q., Pesset, B., Schalk, I.J., et al. Synthesis and antibiotic activity of oxazolidinone–catechol conjugates against Pseudomonas aeruginosa. Org Biomol Chem 13 (2015), 11567–11579.
71. 70 Ghosh, M., Miller, M.J., Synthesis and in vitro antibacterial activity of spermidine-based mixed catechol- and hydroxamate-containing siderophore–vancomycin conjugates. Bioorg Med Chem 4 (1996), 43–48.
72. 71 Wencewicz, T.A., Miller, M.J., Biscatecholate–monohydroxamate mixed ligand siderophore–carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii. J Med Chem 56 (2013), 4044–4052.
73. 72 Mislin, G.L.A., Schalk, I.J., Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosa. Metallomics 6 (2014), 408–420.
74. 73 Kinzel, O., Tappe, R., Gerus, I., Budzikiewicz, H., Synthesis and antibacterial activity of two pyoverdin–ampicillin conjugates, entering Pseudomonas aeruginosa via the pyoverdin-mediated iron uptake pathway. J Antibiot 51 (1998), 499–507.
75. 74 Kinzel, O., Budzikiewicz, H., Synthesis and biological evaluation of a pyoverdin–β-lactam conjugate: a new type of arginine-specific crosslinking in aqueous solution. J Pept Res 53 (1999), 618–625.
76. 75 Hennard, C., Chi Truong, Q., Desnottes, J.-F., Paris, J.-M., Moreau, J.N., Abdallah, M.A., Synthesis and activities of pyoverdin–quinolone adducts: a prospective approach to a specific therapy against Pseudomonas aeruginosa. J Med Chem 44 (2001), 2139–2151.
77. 76 Rivault, F., Liébert, C., Burger, A., Hoegy, F., Abdallah, M.A., Schalk, I.J., et al. Synthesis of pyochelin–norfloxacin conjugates. Bioorg Med Chem Lett 17 (2007), 640–644.
78. 77 Nöel, S., Gasser, V., Pesset, B., Hoegy, F., Rognan, D., Schalk, I.J., et al. Synthesis and biological properties of conjugates between fluoroquinolones and a N3″-functionalized pyochelin. Org Biomol Chem 9 (2011), 8288–8300.
79. 78 Snow, G.A., Mycobactins: iron-chelating growth factors from Mycobacteria. Bacteriol Rev 34 (1970), 99–125.
80. 79 Miller, M.J., Walz, A.J., Zhu, H., Wu, C., Moraski, G., Möllmann, U., et al. Design, synthesis, and study of a mycobactin–artemisinin conjugate that has selective and potent activity against tuberculosis and malaria. J Am Chem Soc 133 (2011), 2076–2079.
81. 80 Juárez-Hernández, R.E., Franzblaub, S.G., Miller, M.J., Syntheses of mycobactin analogs as potent and selective inhibitors of Mycobacterium tuberculosis. Org Biomol Chem 10 (2012), 7584–7593.
82. 81 Zurenko, G.A., Truesdell, S.E., Yagi, B.H., Mourey, R.J., Laborde, A.L., In vitro antibacterial activity and interactions with β-lactamases and penicillin-binding proteins of the new monocarbam antibiotic U-78608. Antimicrob Agents Chemother 34 (1990), 884–888.
83. 82 Brown, M.F., Mitton-Fry, M.J., Arcari, J.T., Barham, R., Casavant, J., Gerstenberger, B.S., et al. Pyridone conjugated monobactam antibiotics with Gram-negative activity. J Med Chem 56 (2013), 5541–5552.
84. 83 Flanagan, M.E., Brickner, S.J., Lall, M., Casavant, J., Deschenes, L., Finegan, S.M., et al. Preparation, Gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. ACS Med Chem Lett 2 (2011), 385–390.
85. 84 Starr, J., Brown, M.F., Aschenbrenner, L., Caspers, N., Che, Y., Gerstenberger, B.S., et al. Siderophore receptor-mediated uptake of lactivicin analogues in Gram-negative bacteria. J Med Chem 57 (2014), 3845–3855.
86. 85 Page, M.G.P., Dantier, C., Desarbre, E., In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli. Antimicrob Agents Chemother 54 (2010), 2291–2302.
87. 86 Page, M.G.P., Dantier, C., Desarbre, E., Gaucher, B., Gebhardt, K., Schmitt-Hoffmann, A., In vitro and in vivo properties of BAL30376, a β-lactam and dual β-lactamase inhibitor combination with enhanced activity against Gram-negative bacilli that express multiple β-lactamases. Antimicrob Agents Chemother 55 (2011), 1510–1519.
88. 87 Hofer, B., Dantier, C., Gebhardt, K., Desarbre, E., Schmitt-Hoffmann, A., Page, M.G.P., Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli. J Antimicrob Chemother 68 (2013), 1120–1129.
89. 88 Page, M.G.P., Siderophore conjugates. Ann N Y Acad Sci 1277 (2013), 115–126.
90. 89 Couvreur, P., Harivardhan, S.B., Reddy, L., Hillaireau, H., Dubernet, C., Desmaelle, D., et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett 6 (2006), 2544–2548.
91. 90 Sémiramoth, N., Di Meo, C., Zouhiri, S.-H.F., Valetti, S., Gorges, R., Nicolas, V., et al. Self-assembled squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular infections. ACS Nano 6 (2012), 3820–3831.
92. 91 Abed, N., Saïd-Hassane, F., Zouhiri, F., Mougin, J., Nicolas, V., Desmaële, D., et al. An efficient system for intracellular delivery of beta-lactam antibiotics to overcome bacterial resistance. Sci Rep, 5, 2015, 13500.
93. 92 Wong, B.S., Yoong, S.L., Jagusiak, A., Panczyk, T., Ho, H.K., Ang, W.H., et al. Carbon nanotubes for delivery of small molecule drugs. Adv Drug Deliv Rev 65 (2013), 1964–2015.
94. 93 Bandow, S., Rao, A.M., Williams, K.A., Thess, A., Smalley, R.E., Eklund, P.C., Purification of single-wall carbon nanotubes by microfiltration. J Phys Chem B 101 (1997), 8839–8842.
95. 94 Chen, R.J., Zhang, Y., Wang, D., Dai, H., Noncovalent sidewall functionalization of single-walled carbon nanotubes for protein immobilization. J Am Chem Soc 123 (2001), 3838–3839.
96. 95 Liu, Z., Winters, M., Holodniy, M., Dai, H., siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed 46 (2007), 2023–2027.
97. 96 Liu, Z., Tabakman, S., Welsher, K., Dai, H., Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery. Nano Res 2 (2009), 85–120.
98. 97 Rosca, I.D., Watari, F., Uo, M., Akasaka, T., Oxidation of multiwalled carbon nanotubes by nitric acid. Carbon 43 (2005), 3124–3131.
99. 98 Moghaddam, M.J., Taylor, S., Gao, M., Huang, S.M., Dai, L.M., McCall, M.J., Highly efficient binding of DNA on the sidewalls and tips of carbon nanotubes using photochemistry. Nano Lett 4 (2004), 89–93.
100. 99 Coleman, K.S., Bailey, S.R., Fogden, S., Green, M.L.H., Functionalization of single-walled carbon nanotubes via the Bingel reaction. J Am Chem Soc 125 (2003), 8722–8723.
101. 100 Tagmatarchis, N., Prato, M., Functionalization of carbon nanotubes via 1,3-dipolar cycloadditions. J Mater Chem 14 (2004), 437–439.
102. 101 Dyke, C.A., Tour, J.M., Overcoming the insolubility of carbon nanotubes through high degrees of sidewall functionalization. Chem Eur J 10 (2004), 812–817.
103. 102 Rosen, Y., Elman, N.M., Carbon nanotubes in drug delivery: focus on infectious diseases. Expert Opin Drug Deliv 6 (2009), 517–530.
104. 103 Wu, W., Wieckowski, S., Pastorin, G., Benincasa, M., Klumpp, C., Briand, J.-P., et al. Targeted delivery of Amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed 44 (2005), 6358–6362.
105. 104 Benincasa, M., Pacor, S., Wu, W., Prato, M., Bianco, A., Gennaro, R., Antifungal activity of amphotericin B conjugated to carbon nanotubes. ACS Nano 5 (2011), 199–208.
106. 105 Prajapati, V.K., Awasthi, K., Gautam, S., Yadav, T.P., Rai, M., Srivastava, O.N., et al. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother 66 (2011), 874–879.
107. 106 Prajapati, V.K., Awasthi, K., Yadav, T.P., Rai, M., Srivastava, O.N., Sundar, S., An oral formulation of Amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis. J Infect Dis 202 (2012), 333–336.
108. 107 Saudagar, P., Dubey, V.K., Carbon nanotube based betulin formulation shows better efficacy against Leishmania parasite. Parasitol Int 63 (2014), 772–776.
109. 108 Zhu, Y.I., Stiller, M.J., Dapsone and sulfones in dermatology: overview an update. J Am Acad Dermatol 45 (2001), 420–434.
110. 109 Sago, J., Hall, R., Dapsone. Dermatol Ther 15 (2002), 340–351.
111. 110 Vukovic, G.D., Tomic, S.Z., Marinkovic, A.D., Radmilovic, V., Uskokovic, P.S., Colic, M., The response of peritoneal macrophages to dapsone covalently attached on the surface of carbon nanotubes. Carbon 48 (2010), 3066–3078.
112. 111 Vashist, S.K., Zheng, D., Pastorin, G., Al-Rubeaan, K., Luong, J.H.T., Sheu, F.-S., Delivery of drugs and biomilecules using carbon nanotubes. Carbon 49 (2011), 4077–4097.
113. 112 Qi, X., Poernomo, G., Wang, K., Chen, Y., Chan-Park, M.B., Xu, R., et al. Covalent immobilization of nisin on multi-walled carbon nanotubes: superior antimicrobial and anti-biofilm properties. Nanoscale 3 (2011), 1874–1880.
114. 113 Yuan, W., Jiang, G., Che, J., Qi, X., Xu, R., Chang, M.W., et al. Deposition of silver nanoparticles on multiwalled carbon nanotubes grafted with hyperbranched poly(amidoamine) and their antimicrobial effects. J Phys Chem C 112 (2008), 18754–18759.
115. 114 Banerjee, I., Mondal, D., Martin, J., Kane, R.S., Photoactivated antimicrobial activity of carbon nanotube–porphyrin conjugates. Langmuir 26 (2010), 17369–17374.
116. 115 Kang, S., Pinault, M., Pfefferle, L.D., Elimelech, M., Single-walled carbon nanotubes exhibit strong antimicrobial activity. Langmuir 23 (2007), 8670–8673.
117. 116 Kang, S., Herzberg, M., Rodrigues, D.F., Elimelech, M., Antibacterial effects of carbon nanotubes: size does matter!. Langmuir 24 (2008), 6409–6413.
118. 117 Yang, C., Mamouni, J., Tang, Y., Yang, L., Antimicrobial activity of single-walled carbon nanotubes: length effect. Langmuir 26 (2010), 16013–16019.
119. 118 Arias, L.R., Yang, L., Inactivation of bacterial pathogens by carbon nanotubes in suspension. Langmuir 25 (2009), 3003–3012.
120. 119 Liu, S., Ng, A.K., Xu, R., Wei, J., Tan, C.M., Yang, Y., et al. Antibacterial action of dispersed single-walled carbon nanotubes on Escherichia coli and Bacillus subtilis investigated by atomic force microscopy. Nanoscale 2 (2010), 2744–2750.
121. 120 Lilly, M., Dong, X., McCoy, E., Yang, L., Inactivation of Bacillus anthracis spores by single-walled carbon nanotubes coupled with oxidizing antimicrobial chemicals. Environ Sci Technol 46 (2012), 13417–13424.
122. 121 Kitchens, K.M., Kolhatkar, R.B., Swaan, P.W., Ghandehari, M., Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2-cells. Mol Pharm 5 (2008), 364–369.
123. 122 Vrignaud, S., Benoit, J.P., Saulnier, P., Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles. Biomaterials 32 (2011), 8593–8604.
124. 123 Wu, L., Ficker, M., Christensen, J.B., Trohopoulos, P.N., Moghimi, S.M., Dendrimers in medicine: therapeutic concepts and pharmaceutical challenges. Bioconjug Chem 26 (2015), 1198–1211.
125. 124 Jain, N.K., Gupta, U., Application of dendrimer–drug complexation in the enhacement of drug solubility and bioavailability. Expert Opin Drug Metab Toxicol 4 (2008), 1035–1052.
126. 125 D'Emanuele, A., Attwood, D., Dendrimer–drug interactions. Adv Drug Deliv Rev 57 (2005), 2147–2162.
127. 126 Mintzer, M.A., Grinstaff, M.W., Biomedical applications of dendrimers: a tutorial. Chem Soc Rev 40 (2011), 173–190.
128. 127 Kaminskas, L.M., Kelly, B.D., McLeod, V.M., Sberna, G., Owen, D.J., Boyd, B.J., et al. Characterisation and tumor targeting og PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. J Control Release 152 (2011), 241–248.
129. 64Cu-labeled LyP-1-dendrimer for PET-CT imaging of atherosclerotic plaque. Bioconjug Chem 25 (2014), 231–239.
130. 129 Navath, R.S., Kurtoglu, Y.E., Wang, B., Kannan, S., Romero, R., Kannan, R.M., Dendrimer–drug conjugates for tailored intracellular drug release based on glutathione levels. Bioconjug Chem 19 (2008), 2446–2455.
131. 130 Sharma, R., Kottari, N., Chabre, Y.M., Abbassi, L., Shiao, T.C., A highly versatile convergent/divergent “onion peel” synthetic strategy toward potent multivalent glycodendrimers. Chem Commun 50 (2014), 13300–13303.
132. N2 reactions. Chem Commun 50 (2014), 1983–1985.
133. 132 Narendra, K.J., Gupta, U., Application of dendrimer–drug complexation in the enhancement of drug solubility and bioavailability. Expert Opin Drug Metab 4 (2008), 1035–1052.
134. 133 Yang, H., Lopina, S.T., Penicillin V-conjugated PEG-PAMAM star polymers. J Biomater Sci Polym Ed 14 (2003), 1043–1056.
135. 134 Bosnjakovic, A., Mishra, M.K., Ren, W., Kurtoglu, Y.E., Shi, T., Fan, D., et al. Poly(amidoamine) dendrimer–erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation. Nanomedicine 77 (2011), 284–294.
136. 135 Mishra, M.K., Kotta, K., Hali, M., Wykes, S., Gerard, H.C., Hudson, A.P., et al. PAMAM dendrimer–azithromycin conjugate nanodevices for the treatment of Chlamydia trachomatis infections. Nanomedicine 7 (2011), 935–944.
137. 136 Ma, M., Cheng, Y., Xu, Z., Xu, P., Qu, H., Fang, Y., et al. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of antibacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur J Med Chem 42 (2007), 93–98.
138. 137 Cheng, Y., Qu, H., Ma, M., Xu, Z., Xu, P., Fang, Y., et al. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobial study: an in vitro study. Eur J Med Chem 42 (2007), 1032–1038.
139. 138 Kumar, P.V., Asthana, A., Dutta, T., Jain, N.K., Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target 14 (2006), 546–556.
140. 139 Kumar, P.V., Agashe, H., Dutta, T., Jain, N.K., PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug. Curr Drug Deliv 4 (2007), 11–19.
141. 140 Bhadra, D., Bhadra, S., Jain, N.K., PEGylated lysine based copolymeric dendritic micelles for solubilization and delivery of artemether. J Pharm Sci 8 (2005), 467–482.
142. 141 Bhadra, D., Yadav, A.K., Bhadra, S., Glycodendrimeric nanoparticulate carriers of primaquine phoshate for liver targeting. Int J Pharm 295 (2005), 221–233.
143. 142 Bhadra, D., Bhadra, S., Jain, N.K., PEGylated peptide dendrimeric carriers for the delivery of antimalarial drug chloroquine phosphate. Pharm Res 23 (2006), 623–633.
144. 143 Agrawal, P., Gupta, U., Jain, N.K., Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials 28 (2007), 3349–3359.
145. 144 Movellan, J., Urbán, P., Moles, E., de la Fuente, J.M., Sierra, T., Serrano, J.L., et al. Amphiphilic dendritic derivatives as nanocarriers for the targeted delivery of antimalarial drugs. Biomaterials 35 (2014), 7940–7950.
146. 145 Winnicka, K., Sosnowska, K., Wieczorek, P., Sacha, P.T., Tryniszewska, T., Poly(amidoamine) dendrimers increase antifungal activity of clotrimazole. Biol Pharm Bull 34 (2011), 1129–1133.
147. 146 Gupta, U., Agashe, H.B., Jain, N.K., Polypropylene imine dendrimer mediated solubility enhacement: effect of pH and functional groups of hydrophobes. J Pharm Pharm Sci 10 (2007), 358–367.
148. 147 Janiszewska, J., Sowińska, M., Rajnisz, A., Solecka, J., Łącka, I., Milewski, S., et al. Novel dendrimeric lipopeptides with antifungal activity. Bioorg Med Chem Lett 22 (2012), 1388–1393.
149. 148 Zielińska, P., Staniszewska, M., Bondaryk, M., Koronkiewicz, M., Urbańczyk-Lipkowska, Z., Design and studies of multiple mechanism of anti-Candida activity of a new potent Trp-rich peptide dendrimers. Eur J Med Chem 105 (2015), 106–119.
150. 149 Dutta, T., Jain, N.K., Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly(propylene imine) dendrimer. Biochim Biophys Acta 2007 (1770), 681–686.
151. 150 Dutta, T., Garg, M., Jain, N.K., Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur J Pharm Sci 34 (2008), 181–189.
152. 151 Landers, J.J., Cao, Z., Lee, I., Piechler, L.T., Myc, P.P., Myc, A., et al. Prevention of influenza pneumonitis by sialic acid-conjugated dendritic polymers. J Infect Dis 186 (2002), 1222–1230.
153. 152 Oka, H., Onaga, T., Koyama, T., Guo, C.-T., Suzuki, Y., Esumi, Y., et al. Sialyl alpha(2 → 3) lactose clusters using carbosilane dendrimer core scaffolds as influenza hemagglutinin blockers. Bioorg Med Chem Lett 18 (2008), 4405–4408.
154. 153 Blanzat, M., Turrin, C.-O., Aubertin, A.-M., Couturier-Vidal, C., Caminade, A.-M., Majoral, J.-P., et al. Dendritic catanionic assemblies: in vitro anti-HIV activity of phosphorus-containing dendrimers bearing Gal(beta)1cer analogues. ChemBioChem 6 (2005), 2207–2213.
155. 154 Lasala, F., Arce, E., Otero, J.R., Rojo, J., Delgado, R., Mannosyl glycodendritic structure inhibits DC-SIGN-mediated Ebola virus infection in cis and trans. Antimicrob Agents Chemother 47 (2003), 3970–3972.
156. 155 Gong, Y., Matthews, B., Cheung, D., Tam, T., Gadawski, I., Leung, D., et al. Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication. Antiviral Res 55 (2002), 319–329.
157. 156 Luganini, A., Nicoletto, S.F., Pizzuto, L., Pirri, G., Giuliani, A., Landolfo, S., et al. Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers. Antimicrob Agents Chemother 55 (2011), 3231–3239.
158. 157 Janout, V., Lanier, M., Regen, S.L., Molecular umbrellas. J Am Chem Soc 118 (1996), 1573–1574.
159. 158 Janout, V., Regen, S.L., Bioconjugate-based molecular umbrellas. Bioconjug Chem 20 (2009), 183–192.
160. 159 Mehiri, M., Chen, W.-H., Janout, V., Regen, S.L., Molecular umbrella transport: exceptions to the classic size/lipophilicity rule. J Am Chem Soc 131 (2009), 1338–1339.
161. 160 Ge, G., Wu, D., Wang, Z., Shi, W., Wu, T., Zhang, A., et al. Cellular uptake mechanism of molecular umbrella. Bioconjug Chem 20 (2009), 2311–2316.
162. 161 Janout, V., Di Giorgio, C., Regen, S.L., Molecular umbrella-assisted transport of a hydrophilic peptide across a phospholipid membrane. J Am Chem Soc 122 (2000), 2671–2672.
163. 162 Janout, V., Zhang, L.H., Staina, I.V., Di Giorgio, C., Regen, S.L., Molecular umbrella-assisted transport of glutathione across a phospholipid membrane. J Am Chem Soc 123 (2001), 5401–5406.
164. 163 Janout, V., Jing, B., Regen, S.L., Molecular umbrella-assisted transport of thiolated AMP and ATP across phospholipid bilayers. Bioconjug Chem 13 (2002), 351–356.
165. 164 Jing, B., Janout, V., Herold, B.C., Klotman, M.E., Heald, T., Regen, S.L., Persulfated molecular umbrellas as anti-HIV and anti-HSV agents. J Am Chem Soc 126 (2004), 15930–15931.
166. 165 Madan, R.P., Mesquita, P.M.M., Cheshenko, N., Jing, B., Shende, V., Guzman, E., et al. Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol 81 (2007), 7636–7646.
167. 166 Yamashita, K., Janout, V., Bernard, E.M., Armstrong, D., Regen, S.L., Micelle/monomer control over the membrane-disrupting properties of an amphiphilic antibiotic. J Am Chem Soc 117 (1995), 6249–6253.
168. 167 Liu, Y., Regen, S.L., Control over vesicle rapture and leakage by membrane packing and by the aggregation state of an attacking surfactant. J Am Chem Soc 115 (1993), 708–713.
169. 168 Juliano, R.L., Grant, C.W., Barber, K.R., Kalp, M.A., Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 31 (1987), 1–11.
170. 169 Janout, V., Bienvenu, C., Schell, W., Perfect, J.R., Regen, S.L., Molecular umbrella–amphotericin B conjugates. Bioconjug Chem 25 (2014), 1408–1411.
171. 170 Janout, V., Schell, W.A., Thevenin, D., Yu, Y., Perfect, J.R., Regen, S.L., Taming amphotericin B. Bioconjug Chem 26 (2015), 2021–2024.
172. 171 De Carvalho, C.C.C.R., Fernandes, P., Siderophores as “Trojan Horses”: tackling multidrug resistance?. Front Microbiol, 5, 2014, e290.
173. 172 Górska, A., Sloderbach, A., Marszałł, M.P., Siderophore–drug complexes: potential medicinal applications of the ‘Trojan horse’ strategy. Trends Pharmacol Sci 35 (2014), 442–449.